Clinical Trial Update: Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment [Phase 3]

View source ↗

Summary

Phase 3 open-label safety study of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) in HIV-1 patients with mild to moderate renal impairmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Genvoya (elvitegravir; cobicistat; emtricitabine; tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2016-02-18